Blog

The HepMag article from 08/27/2026 titled “Rural Americans Face Worsening Liver Cancer Disparities” is revealing. The article highlights a growing rural–urban divide in hepatocellular carcinoma (HCC), the most common form… Read more: Rural Liver Cancer Disparities

HHS Announces Winners of the 2026 KidneyX EMPOWER: Living Link Prize Challenge to Advance Living Kidney Donation and Patient-Centered Innovation “WASHINGTON, D.C. — August 27, 2026 — The U.S. Department… Read more: KidneyX EMPOWER Winners

Find out soonest, we say.

The 2025 State of Steatotic Liver Care survey from the Steatotic Liver Foundation paints a clear picture: liver disease is still being detected too late, and many diagnosed patients never… Read more: State of Fatty Liver Care

This June 2026 article in Hepatobiliary & Pancreatic Diseases International titled “Combined Bio-histological assessment as a tool to refine diagnosis and avoid overtreatment of early T cell-mediated rejection after liver… Read more: Post Liver Transplant New Scoring Tool

Summary: Lean Fatty Liver May Still Carry Meaningful Liver Risk A large multinational study highlighted by GI & Hepatology News (Aug. 12, 2026), titled “Lean steatosis without metabolic risk factors… Read more: Lean Fatty Liver

The Liver Disease News article, “Signs your liver is healing from MASLD,” makes a useful patient-facing point: the liver can recover substantially—especially when MASLD is identified before advanced fibrosis/cirrhosis—but symptoms… Read more: Liver Healing

This study titled “Xenobiotic-Induced Liver Injury in the United States: A 25-Year Retrospective Analysis of National Poison Data System” looked at 25 years of U.S. poison-center data to see how… Read more: Poison-Center Data and Liver Injury

The 08/13/2026 WIRED article titled “There’s a Fatty Liver Epidemic. AI Could Help Get Ahead of It” argues that fatty liver disease has become a massive, largely silent public-health problem:… Read more: Wired Article on Hep & AI

This 08/12/2026 article titled “Energy Drink-Associated Mixed Liver Injury With Cholestatic Histology After Long-Term High-Volume Consumption: A Case Report” is a case report of probable energy drink–associated drug-induced liver injury… Read more: Energy Drinks and Liver Health

Summary The June 19, 2026 articled titled “Spatial transcriptome mapping identifies Ppara-Anxa2 cross-talk in microplastic-induced hepatotoxicity” is edifying. A new preclinical study suggests that polyethylene (PE) microplastics may directly disrupt… Read more: Microplastics and Liver Metabolism

Published August 7, 2026 in Nature Reviews Gastroenterology & Hepatology, “The dynamic spectrum of steatotic liver disease: the global perspective“ makes an important point for patients: fatty liver disease is… Read more: Fatty Liver Disease a Spectrum Not a Label

Here’s a concise summary of the RADx® Tech Independent Test Assessment Program (ITAP) for Hepatitis C Virus (HCV) RNA Near-Patient Diagnostics (2026): Executive Summary The NIH/NIBIB RADx® Tech Independent Test… Read more: RADx® Tech Independent Test Assessment Program for Hepatitis C Virus RNA Near-Patient Diagnostics

Here’s a plain-English summary of the article titled “Liver Imaging Reporting and Data System (LI-RADS): A Comprehensive Review,” from Cureus, dated 07/31/2026, for patients and families: Understanding LI-RADS: A Guide… Read more: LI-RADS Explained

The paper titled “Comparison of Factors Associated With 30-Day and 90-Day Readmission Among a Global Cohort of Patients Hospitalised With Cirrhosis” is a large international prospective study examining what predicts… Read more: Hospital Readmits in Cirrhosis

Details here: https://www.who.int/campaigns/world-hepatitis-day/2026

The 05/27/2026 article “GLP-1s Gain Traction for Treating Fatty Liver Disease” central message is that GLP-1 receptor agonists (particularly semaglutide/Wegovy and tirzepatide) are rapidly moving from “weight-loss drugs” to becoming… Read more: Fatty Liver and GLP-1s

July 23, 2026: Medscape In Discussion: MASLD. This video speaks to when fatty liver appears incidentally on imaging, “just lose weight” isn’t enough. Dr. Danielle Brandman of Weill Cornell Medicine… Read more: Incidental Finding in Imaging: Liver

Summary: “Researchers Recommend Dynamic Classification for Steatotic Liver Disease“ Published: July 21, 2026 (CLP Magazine)Based on research from: Charité – Universitätsmedizin Berlin, published in eGastroenterology The big idea The researchers… Read more: New Classification Rubric for Liver Disease

The paper “Steatotic Liver Disease Has Surpassed Viral Hepatitis as the Leading Cause of Cirrhosis in the U.S. Veterans Health System“ (American Journal of Gastroenterology, 2026) analyzed all U.S. Veterans… Read more: Cirrhosis in the VA

A new UC San Diego-led study titled “GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease” provides encouraging evidence that GLP-1 receptor agonists may benefit patients with advanced metabolic… Read more: GLP-1 Effect in Liver

Give this article a read: “Chronic Liver Disease: How PCPs Can Improve Early Detection.” This HCPLive interview with Stevan Gonzalez, MD, MS (Director of Liver Transplantation at Baylor Scott &… Read more: Liver Disease: Screenalot

Here’s a summary of the paper titled: Machine Learning–Assisted Detection of Advanced Liver Fibrosis in Primary Care (2025) One-sentence summary The study found that an AI/machine learning approach applied to… Read more: Find HCC Earlier

The LinkedIn article titled “Trinity Health Aims to Improve Liver Cancer Screening Rates Through Physician, Patient Education Intervention” highlights a small but potentially high-impact initiative by Trinity Health West Michigan… Read more: Trinity Health Innovation in HCC

This new Clinical Gastroenterology and Hepatology (CGH) study is one of the strongest observational studies to date examining coffee and liver health because it combines long-term clinical outcomes with liver… Read more: Coffee and Liver Health

The PharmaVoice article titled “3 late-stage MASH drugs that could rival Rezdiffra” highlights the next wave of MASH therapies expected to compete with Madrigal’s Rezdiffra (resmetirom), emphasizing that the future… Read more: New MASH Drugs

Here are the key takeaways from the HCPLive article, “Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework,” by Dr. Zobair Younossi (published June 23, 2026). 1. MASLD… Read more: MASLD Treatment: New Era